Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 0 037 IN SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 0 037 IN SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs POTASSIUM CHLORIDE 0.037% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate provides magnesium ions, which are essential for various physiological processes. It acts as a cofactor for enzymatic reactions, stabilizes excitable membranes, and antagonizes calcium entry at the neuromuscular junction, leading to reduced acetylcholine release and muscle relaxation. In the CNS, it may act as a noncompetitive antagonist of NMDA receptors, exerting anticonvulsant effects.
Potassium chloride provides a source of potassium ions, which are essential for maintaining intracellular tonicity, nerve impulse conduction, muscle contraction, and acid-base balance. Sodium chloride provides sodium and chloride ions, which are necessary for maintaining extracellular fluid volume and osmolality.
1 to 4 g intravenously as a 5% to 20% solution, rate not exceeding 150 mg/min; dosing frequency depends on indication (e.g., preeclampsia/eclampsia: 4-5 g IV loading then 1-2 g/hr infusion; hypomagnesemia: 1-2 g IV over 1-2 hours, may repeat based on serum magnesium levels).
Intravenous infusion: 0.037% potassium chloride in 0.9% sodium chloride solution; rate not to exceed 10 mEq/hour (or 10 mmol/hour) potassium; typical adult dose 20-40 mEq per day, adjusted based on serum potassium levels.
None Documented
None Documented
Terminal half-life approximately 4-5 hours in normal renal function; prolonged in renal impairment (up to 40 hours).
Potassium: Not applicable as endogenous ion with tight homeostatic control; administered potassium distributes rapidly and is eliminated with a functional half-life of about 1-2 hours in the central compartment due to redistribution and renal excretion, but total body potassium turnover half-life is approximately 20-30 days. Sodium: Not applicable; administered sodium is rapidly equilibrated and renally regulated.
Primarily renal (90-100% as unchanged magnesium). Less than 1% biliary/fecal.
Renal excretion of potassium is the primary route (approximately 90% of daily intake), with minimal fecal loss (about 10%). The sodium component is also predominantly renally excreted, with >99% of filtered sodium reabsorbed under normal conditions.
Category C
Category A/B
Electrolyte
Electrolyte